🔓 Unlock the full profile of Derek Maetzold (Castle Biosciences, Inc.), including verified contact details, financial insights, and professional associations.
See Derek Maetzold Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: der*****@cas******.com
Mobile: 82650*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Derek Maetzold is the President, CEO, and Founder of Castle Biosciences, Inc., an innovative company established in 2008, focusing on developing diagnostic and prognostic tests for skin cancers and other conditions.
- Under the leadership of Derek Maetzold, Castle Biosciences has significantly impacted the field of dermatology by providing actionable insights and personalized treatment options for patients, enhancing patient care and outcomes.
- Castle Biosciences became publicly traded on NASDAQ under the symbol CSTL, reflecting its growth and expanding influence in the healthcare sector.
- Derek has served on the Board of Directors for various organizations, including IMPACT Melanoma and PreludeDx, showcasing a commitment to advancing melanoma awareness and improving diagnostic capabilities.
- As a member of the Board of Directors for The Coalition for 21st Century Medicine starting in March 2024, Derek will contribute to dialogues and initiatives focused on modernizing medical practices through innovative technologies.
- Prior to founding Castle Biosciences, Derek held key leadership roles at companies such as Encysive Pharmaceuticals and Schering-Plough, acquiring extensive experience in sales and marketing within the pharmaceutical industry.
- Derek's tenure at Castle Biosciences has included the successful development and commercialization of tests such as DecisionDx-Melanoma, which aids in assessing the risk of recurrence in melanoma patients.
- The company has achieved noteworthy recognition and growth, with a reported market capitalization of 496.9 million, highlighting its importance in the biomedical landscape.
- Derek Maetzold has demonstrated a deep commitment to advancing healthcare diagnostics, addressing challenges within the industry, and fostering an environment of innovation through leadership roles and strategic initiatives.